Your browser doesn't support javascript.
Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants.
Sun, Cong; Kang, Yin-Feng; Liu, Yuan-Tao; Kong, Xiang-Wei; Xu, Hui-Qin; Xiong, Dan; Xie, Chu; Liu, Yi-Hao; Peng, Sui; Feng, Guo-Kai; Liu, Zheng; Zeng, Mu-Sheng.
  • Sun C; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, 510060, P. R. China.
  • Kang YF; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, 510060, P. R. China.
  • Liu YT; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, 510060, P. R. China.
  • Kong XW; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, 510060, P. R. China.
  • Xu HQ; Cryo-electron Microscopy Center, Southern University of Science and Technology, Shenzhen, 518000, Guangdong, P. R. China.
  • Xiong D; Medical Laboratory of the Third affiliated Hospital of Shenzhen University, Shenzhen, 518000, Guangdong, P. R. China.
  • Xie C; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Experimental Research, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, 510060, P. R. China.
  • Liu YH; Institute of Precision Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, Guangdong, P. R. China.
  • Peng S; Clinical Trials Unit, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, Guangdong, P. R. China.
  • Feng GK; Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, Guangdong, P. R. China.
  • Liu Z; Institute of Precision Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, Guangdong, P. R. China.
  • Zeng MS; Clinical Trials Unit, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, Guangdong, P. R. China.
Signal Transduct Target Ther ; 7(1): 42, 2022 02 08.
Article in English | MEDLINE | ID: covidwho-1683981
ABSTRACT
SARS-CoV-2 variants have evolved a variety of critical mutations, leading to antigenicity changes and immune escape. The recent emerging SARS-CoV-2 Omicron variant attracted global attention due to its significant resistance to current antibody therapies and vaccines. Here, we profiled the mutations of Omicron and other various circulating SARS-CoV-2 variants in parallel by computational interface analysis and in vitro experimental assays. We identified critical mutations that lead to antigenicity changes and diminished neutralization efficiency of a panel of 14 antibodies due to diverse molecular mechanisms influencing the antigen-antibody interaction. Our study identified that Omicron exhibited extraordinary potency in immune escape compared to the other variants of concern, and explores the application of computational interface analysis in SARS-CoV-2 mutation surveillance and demonstrates its potential for the early identification of concerning variants, providing preliminary guidance for neutralizing antibody therapy.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Immune Evasion / SARS-CoV-2 / COVID-19 / Antibodies, Viral / Antigens, Viral Topics: Vaccines / Variants Limits: Humans Language: English Journal: Signal Transduct Target Ther Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / Immune Evasion / SARS-CoV-2 / COVID-19 / Antibodies, Viral / Antigens, Viral Topics: Vaccines / Variants Limits: Humans Language: English Journal: Signal Transduct Target Ther Year: 2022 Document Type: Article